Ocular Therapeutix Inc Stock Research

Market Summary

USD6.92+0.50

Market Closed

7.79%

OCUL Alerts

Big fall in earnings (Y/Y)
Losses in recent quarter

OCUL Stock Price

OCUL RSI Chart

OCUL Valuation

Market Cap

536.4M

Price/Earnings (Trailing)

-6.04

Price/Sales (Trailing)

10.38

Price/Free Cashflow

-7.91

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-200.79%

Return on Assets

-47.58%

Free Cashflow Yield

-12.64%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

51.7M

Revenue Y/Y

1.42%

Revenue Q/Q

-4.98%

OCUL Earnings

Earnings (TTM)

-88.8M

Earnings Y/Y

-141.73%

Earnings Q/Q

-95.07%

Price Action

52 Week Range

2.577.32

(Low)(High)

Last 7 days

10.2%

Last 30 days

11.8%

Last 90 days

17.1%

Trailing 12 Months

117.6%

OCUL Financial Health

Current Ratio

4.13

OCUL Investor Care

Shares Dilution (1Y)

0.99%

Diluted EPS (TTM)

-1.19

Peers (Alternatives to Ocular Therapeutix)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	409.0B	96.3B	-3.62%	-9.57%	32.14	4.25	1.46%	-35.83%
LLY	398.5B	27.7B	2.58%	47.15%	70.08	14.39	-5.56%	-7.22%
MRK	272.8B	57.9B	-4.82%	28.79%	17.88	4.63	7.21%	-8.11%
PFE	230.9B	93.0B	-0.23%	-25.99%	7.36	2.3	0.56%	16.36%
BMY	150.1B	45.8B	-1.47%	-11.26%	23.72	3.25	-2.37%	16.96%
MID-CAP
PRGO	5.0B	4.6B	-12.00%	-16.92%	-35.25	1.11	8.46%	-29.07%
RETA	3.5B	1.5M	-8.84%	225.36%	-11.32	1.6K	-86.94%	-16.59%
SMALL-CAP
SUPN	1.8B	668.5M	-9.91%	19.28%	34.95	2.72	11.17%	-29.04%
TLRY	1.6B	596.3M	-7.75%	-62.41%	-0.89	2.66	-3.41%	-3791.67%
INVA	866.9M	271.5M	14.22%	-13.24%	3.94	3.19	-31.50%	-40.28%
CRON	666.4M	112.3M	-6.91%	-41.08%	-4.29	5.94	7.69%	41.96%
ACRS	590.7M	30.8M	-2.33%	-39.30%	-6.14	19.16	378.90%	-19.01%
OCUL	536.4M	51.7M	11.79%	117.61%	-6.04	10.38	4.69%	-299.77%
CGC	401.1M	478.9M	-31.81%	-82.48%	-0.13	0.84	-31.50%	-634.70%
ENDP	94.1M	2.2B	-43.99%	-88.43%	-0.03	0.04	-25.47%	-292.77%

Financials for Ocular Therapeutix

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	0.4%	51,680	51,494	49,726	49,914	49,366
S&GA Expenses	4.4%	41,693	39,922	38,525	37,915	36,166
R&D Expenses	3.1%	55,109	53,462	52,497	51,497	52,256
Interest Expenses	1.2%	7,108	7,022	6,856	6,717	6,676
Net Income	-25.0%	-88,814	-71,038	-59,346	-32,501	-22,216
Net Income Margin	-15.6%	-1.38*	-1.19*	-0.65*	-0.45*	-
Free Cahsflow	-5.5%	-63,318	-59,994	-59,289	-68,103	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-13.9%	129	149	159	173	188
Current Assets	-17.3%	107	130	146	160	175
Cash Equivalents	-21.0%	81.00	102	121	135	145
Inventory	14.8%	2.00	2.00	2.00	2.00	1.00
Net PPE	22.0%	12.00	10.00	7.00	7.00	7.00
Liabilities	4.3%	119	114	112	107	108
Current Liabilities	-5.4%	30.00	31.00	29.00	26.00	24.00
Shareholder's Equity	-72.6%	10.00	35.00	46.00	66.00	80.00
Retained Earnings	-4.9%	-647	-616	-601	-577	-558
Additional Paid-In Capital	0.7%	657	652	648	643	638
Shares Outstanding	0.4%	78.00	77.00	77.00	77.00	77.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-2.3%	-60,976	-59,603	-57,798	-57,611	-66,791
Share Based Compensation	2.1%	17,327	16,964	16,571	16,089	16,100
Cashflow From Investing	-83.5%	-6,818	-3,715	-2,196	-1,678	-1,312
Cashflow From Financing	-3.5%	1,403	1,454	1,663	1,968	4,142

Risks for OCUL

What is the probability of a big loss on OCUL?

98.8%

Probability that Ocular Therapeutix stock will be more than 20% underwater in next one year

97.3%

Probability that Ocular Therapeutix stock will be more than 30% underwater in next one year.

72.3%

Probability that Ocular Therapeutix stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OCUL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ocular Therapeutix was unfortunately bought at previous high price.

Drawdowns

Returns for OCUL

Cumulative Returns on OCUL

-7.4%

7-Year Cumulative Returns

0.3%

5-Year Cumulative Returns

-0.7%

3-Year Cumulative Returns

What are the long-term rolling returns for OCUL?

FIve years rolling returns for Ocular Therapeutix.

Annualized Returns

Which funds bought or sold OCUL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-11.52	30,172	75,930	-%
2023-05-22	AMERIPRISE FINANCIAL INC	added	16.51	101,663	186,663	-%
2023-05-18	JPMORGAN CHASE & CO	added	38.69	207,000	337,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-41.11	16,000	166,000	-%
2023-05-17	Advisory Services Network, LLC	unchanged	-	615	1,318	-%
2023-05-16	ATLAS CAPITAL ADVISORS LLC	unchanged	-	12,300	26,350	-%
2023-05-16	JANE STREET GROUP, LLC	added	323	539,212	616,832	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	84.87	917,179	1,288,930	-%
2023-05-15	Cubist Systematic Strategies, LLC	new	-	226,552	226,552	-%
2023-05-15	Quantamental Technologies LLC	new	-	70,254	70,254	0.04%

Latest Funds Activity

Are funds buying OCUL calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own OCUL

No. of Funds

Ocular Therapeutix News

Schedule 13G FIlings of Ocular Therapeutix

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	opaleye management inc.	7.89%	6,075,000	SC 13G/A
Feb 09, 2023	vanguard group inc	5.16%	3,976,853	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	4,952,737	SC 13G/A
Feb 03, 2022	blackrock inc.	6.7%	5,122,835	SC 13G/A
Feb 01, 2022	opaleye management inc.	7.80%	5,974,800	SC 13G/A
Feb 12, 2021	opaleye management inc.	8.65%	9	SC 13G/A
Feb 02, 2021	blackrock inc.	7.3%	5,512,264	SC 13G
Jun 09, 2020	blackrock inc.	4.8%	3,006,167	SC 13G/A
May 21, 2020	summer road llc	17.0%	11,387,656	SC 13D/A
Mar 25, 2020	summer road llc	18.9%	11,024,020	SC 13D/A

OCUL Fair Value

Show Fair-Value

Recent SEC filings of Ocular Therapeutix

View All Filings

Date Filed	Form Type	Document
May 08, 2023	8-K	Current Report
May 08, 2023	10-Q	Quarterly Report
May 01, 2023	DEFA14A	DEFA14A
May 01, 2023	DEF 14A	DEF 14A
May 01, 2023	ARS	ARS
Apr 06, 2023	8-K	Current Report
Mar 06, 2023	S-8	Employee Benefits Plan
Mar 06, 2023	8-K	Current Report
Mar 06, 2023	10-K	Annual Report

Latest Insider Trading transactions for OCUL

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-06	Mattessich Antony C.	sold	-83,396	4.24	-19,669	president and ceo
2023-02-06	White Christopher G	sold	-24,715	4.24	-5,829	chief business officer
2023-02-06	Ozden Rabia Gurses	sold	-27,203	4.24	-6,416	chief medical officer
2023-02-06	Notman Donald	sold	-27,458	4.24	-6,476	chief financial officer
2023-02-06	Strassburger Philip C.	sold	-26,207	4.24	-6,181	general counsel
2023-01-30	Notman Donald	acquired	-	-	55,556	chief financial officer
2023-01-30	Ozden Rabia Gurses	acquired	-	-	55,556	chief medical officer
2023-01-30	Strassburger Philip C.	acquired	-	-	55,556	general counsel
2023-01-30	Mattessich Antony C.	acquired	-	-	176,300	president and ceo
2023-01-30	White Christopher G	acquired	-	-	44,444	chief business officer

About Ocular Therapeutix

Antony Mattessich

www.ocutx.com

230

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue, net	$ 13,374	$ 13,187
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Product	Product
Cost of product revenue	$ 1,214	$ 1,300
Research and development	14,747	13,100
Selling and marketing	10,835	9,063
General and administrative	9,127	7,557
Total costs and operating expenses	35,923	31,020
Loss from operations	(22,549)	(17,833)
Other income (expense):
Interest income	563	18
Interest expense	(1,768)	(1,683)
Change in fair value of derivative liability	(6,563)	6,958
Other expense, net	(1)	(2)
Total other (expense) income, net	(7,769)	5,291
Net loss	$ (30,318)	$ (12,542)
Net loss per share, basic	$ (0.39)	$ (0.16)
Weighted average common shares outstanding, basic	77,386,287	76,745,663
Net loss per share, diluted	$ (0.39)	$ (0.22)
Weighted average common shares outstanding, diluted	77,386,287	82,514,895
Product
Revenue:
Total revenue, net	$ 13,214	$ 12,498
Collaboration revenue
Revenue:
Total revenue, net	$ 160	$ 689

OCUL Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 79,026	$ 102,300
Accounts receivable, net	21,124	21,325
Inventory	2,266	1,974
Prepaid expenses and other current assets	4,746	4,028
Total current assets	107,162	129,627
Property and equipment, net	12,022	9,856
Restricted cash	1,764	1,764
Operating lease assets	7,625	8,042
Total assets	128,573	149,289
Current liabilities:
Accounts payable	5,441	5,123
Accrued expenses and other current liabilities	21,993	24,097
Deferred revenue	463	576
Operating lease liabilities	1,818	1,599
Total current liabilities	29,715	31,395
Other liabilities:
Operating lease liabilities, net of current portion	8,114	8,678
Derivative liability	12,914	6,351
Deferred revenue, net of current portion	13,340	13,387
Notes payable, net of discount	25,321	25,257
Other non-current liabilities	100	93
2026 convertible notes, net	29,358	28,749
Total liabilities	118,862	113,910
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 77,516,638 and 77,201,819 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	8	8
Additional paid-in capital	656,863	652,213
Accumulated deficit	(647,160)	(616,842)
Total stockholders' equity	9,711	35,379
Total liabilities and stockholders' equity	$ 128,573	$ 149,289